PMID- 11724329
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20061115
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 21
IP  - 4A
DP  - 2001 Jul-Aug
TI  - Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and 
      regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of 
      tumor-induced immunosuppression?
PG  - 2609-15
AB  - BACKGROUND: Deregulation of MHC class II molecules consists of a favorable 
      mechanism of tumor evasion from immune surveillance. Among these molecules, 
      HLA-DR antigens are the predominant ones in cancer. In the present study we 
      sought to investigate the ability of tumor infiltrating immune cells (TIICs) to 
      express HLA-DR antigen in the primary tumor site and reactive regional lymph 
      nodes (LNs) in non small cell lung cancer (NSCLC). MATERIALS AND METHODS: 
      Material consisting of 60 NSCLCs with corresponding regional LNs was studied by 
      immunohistochemistry for human leukocyte antigen D-region related (HLA-DR) 
      expression. Control reactive LNs, regional to several different malignant and 
      non-malignant disorders, were also included in the study. RESULTS: Primary tumor 
      site investigation revealed positive HLA-DR cancer cells in 22% of cases, whereas 
      TIICs rarely expressed HLA-DR antigens. The lack of HLA-DR expression in TIICs 
      was gradually attenuated as the distance from the primary tumor site decreased. 
      Regional LN investigation showed that all follicles (paracapsular and deep 
      cortical ones) were HLA-DR-negative in 60% of the LNs; in the remaining 40%, the 
      paracapsular follicles remained negative, while all deep cortical ones were 
      positive. Interestingly, LNs possessing only HLA-DR-negative follicles were more 
      proximal to the primary tumor site compared to those that had only the 
      paracapsular follicles negative. All control reactive LNs, regional to several 
      distinct malignant and non-malignant disorders, were found to be HLA-DR-positive. 
      CONCLUSION: The impairment of HLA-DR expression, detected both in neoplastic and 
      by-stander immune cells, may justify the immunosuppression observed in NSCLC. 
      This phenomenon may be due to a putative soluble factor in the tumor environment 
      secreted by cancer cells.
FAU - Foukas, P G
AU  - Foukas PG
AD  - Department of Histology and Embryology, Medical School, University of Athens, 
      Greece.
FAU - Tsilivakos, V
AU  - Tsilivakos V
FAU - Zacharatos, P
AU  - Zacharatos P
FAU - Mariatos, G
AU  - Mariatos G
FAU - Moschos, S
AU  - Moschos S
FAU - Syrianou, A
AU  - Syrianou A
FAU - Asimacopoulos, P J
AU  - Asimacopoulos PJ
FAU - Bramis, J
AU  - Bramis J
FAU - Fotiadis, C
AU  - Fotiadis C
FAU - Kittas, C
AU  - Kittas C
FAU - Gorgoulis, V G
AU  - Gorgoulis VG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (HLA-DR Antigens)
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*immunology/metabolism
MH  - HLA-DR Antigens/biosynthesis/*immunology
MH  - Humans
MH  - Immune Tolerance/immunology
MH  - Immunohistochemistry
MH  - Killer Cells, Natural/immunology/metabolism
MH  - Lung Neoplasms/*immunology/metabolism
MH  - Lymph Nodes/immunology/metabolism
MH  - Lymphocytes, Tumor-Infiltrating/*immunology/metabolism
MH  - Macrophages/immunology/metabolism
EDAT- 2001/11/29 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/29 10:00
PHST- 2001/11/29 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/29 10:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2001 Jul-Aug;21(4A):2609-15.